Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19979099 | 1.00 | LMNA (0.44) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL19974452 | 0.92 | LMNA (0.47) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL22700215 | 0.91 | ALDH1A1 (0.44) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL19974563 | 0.86 | HINT1 (0.40) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL29148038 | 0.85 | LMNA (0.48) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL30303123 | 0.85 | LMNA (0.48) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL18041225 | 0.85 | LMNA (0.48) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL17467485 | 0.85 | LMNA (0.48) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL22700325 | 0.85 | LMNA (0.42) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL20305220 | 0.85 | LMNA (0.47) | LMNAALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434255-B2 | Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent | LCB PHARMA INC. (CA) | 2022-09-06 | — | — | US | disclosed |
| EP-3512860-B1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC (CA) | 2020-11-25 | — | — | EP | disclosed |
| EP-3512860-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB Pharma Inc. (CA) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018049534-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434255-B2 | Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent | TNNT2, NT5C2, PNP | LMNA 144/4885ALDH1A1 3260/4885TP53 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.